Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business UpdatesGlobeNewsWire • 02/27/23
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS MutationsGlobeNewsWire • 11/28/22
Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/10/22
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/10/22
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITCGlobeNewsWire • 11/10/22
These Are the Five Best and Worst Performing Small-cap Stocks in September 202224/7 Wall Street • 10/22/22
These Were The Five Best And Worst Performing Healthcare Stocks In September 202224/7 Wall Street • 10/17/22
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 10/05/22
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS MutationsGlobeNewsWire • 09/30/22
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?Zacks Investment Research • 09/12/22
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS MutationsGlobeNewsWire • 09/02/22
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to TradeZacks Investment Research • 08/25/22
Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/10/22
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/10/22
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022GlobeNewsWire • 07/06/22
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104GlobeNewsWire • 05/26/22